Margaret Wooddell
Overview
Explore the profile of Margaret Wooddell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
47
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Desai J, Wagner A, Carrasco Garcia I, Cesari M, Gordon M, Lin C, et al.
Cancer
. 2024 Nov;
131(1):e35634.
PMID: 39533157
Background: Pexidartinib is effective in patients with tenosynovial giant cell tumor (TGCT) for whom surgery is not feasible. Durability of response after discontinuation of pexidartinib and the safety and efficacy...
2.
Dharmani C, Fofah O, Fallon M, Rajper A, Wooddell M, Salas M
Future Oncol
. 2024 Jul;
20(33):2559-2564.
PMID: 39023446
Hepatic safety data assessment from the TURALIO (pexidartinib) Risk Evaluation and Mitigation Strategy (tREMS) Program. Retrospective 3-year assessment (August 2019 to June 2022) of hepatic events from the TURALIO® (pexidartinib)...
3.
Dharmani C, Fofah O, Wang E, Salas M, Wooddell M, Tu N, et al.
Future Oncol
. 2024 Feb;
20(16):1079-1097.
PMID: 38380590
Real-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the only US FDA-approved treatment for TGCT associated with severe morbidity or functional limitations and not...
4.
Dharmani C, Unni S, Pham N, Shaikh N, Xiong Y, Vashi R, et al.
Future Oncol
. 2023 Oct;
20(15):1013-1030.
PMID: 37814886
To evaluate treatment patterns, healthcare resource utilization (HRU) and costs among peripheral T-cell lymphoma (PTCL) patients in the USA. A retrospective cohort study, using the IQVIA PharMetrics Plus claims database...
5.
Boluda B, Solana-Altabella A, Cano I, Martinez-Cuadron D, Acuna-Cruz E, Torres-Minana L, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190195
The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to...
6.
Fitzpatrick L, Bilezikian J, Wooddell M, Paul G, Kolatkar N, Nino A, et al.
J Drug Assess
. 2016 Aug;
1(1):11-9.
PMID: 27536422
Objectives: Post-hoc analyses have shown an increase incidence of fractures among type 2 diabetes (T2DM) patients treated with thiazolidinediones (TZDs). The mechanisms by which TZDs may be associated with increased...
7.
Fitzpatrick L, Wooddell M, Dabrowski C, Cicconetti G, Gordon D
Bone
. 2014 May;
67:104-8.
PMID: 24794093
Context: Parathyroidectomy in patients with hyperparathyroidism can produce subsequent increases in bone mineral density (BMD). Ronacaleret, a selective calcium-sensing receptor antagonist that stimulates endogenous parathyroid hormone release, induced mild hyperparathyroidism....
8.
Bilezikian J, Josse R, Eastell R, Lewiecki E, Miller C, Wooddell M, et al.
J Clin Endocrinol Metab
. 2013 Mar;
98(4):1519-28.
PMID: 23450056
Context: Postmenopausal status and type 2 diabetes mellitus (T2DM) are independent risk factors for fractures. An increased fracture risk has been observed with rosiglitazone (RSG), a thiazolidinedione, in patients with...